Simcere Pharma Moves Closer to International Sales With Approval for Diarrhea Drug

| About: Simcere Pharmaceutical (SCR)

Simcere Pharma (NYSE: SCR) reported that diosmectite, the API in its branded generic diarrhea drug Biqi, has passed EU-GMP inspection. Diosmectite is made from a natural mineral, and Simcere owns a high-grade diosmectite mine in China. It is the leading anti-diarrhea drug in China and France.

Simcere positioned the approval as important to the company’s initiative to develop international sales, which in the past have not been an important factor in the company’s revenues.

Disclosure: none.